October 13, 2018

RENB: Renovaro Inc. Stock

by Wilton Risenhoover

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M)	96.87
Enterprise Value ($M)	99.35
Book Value ($M)	98.09
Book Value / Share	0.62
Price / Book	0.99
NCAV ($M)	-21.80
NCAV / Share	-0.14
Price / NCAV	-4.44

Profitability (mra)
Return on Invested Capital (ROIC)	-1.13
Return on Assets (ROA)	-2.01
Return on Equity (ROE)	-2.47

Liquidity (mrq)
Quick Ratio	0.08
Current Ratio	0.08

Balance Sheet (mrq) ($M)
Current Assets	1.95
Assets	121.83
Liabilities	23.75
Debt	n/a
Equity	n/a

Income Statement (mra) ($M)
Revenue	0.00
Operating Income	-27.39
Net Income	-80.65
Earnings Per Share Basic And Diluted	n/a

Cash Flow Statement (mra) ($M)
Cash From Operations	-10.97
Cash from Investing	-1.26
Cash from Financing	10.52
(click for more detail)

File Date	Form	Activist 13D/G Investors	Ownership (%)	Change (%)
11-06	13D/A	William Anderson Wittekind	11.40	0.00
02-22	13G/A	Abildgaard Ole	7.60	9.84
02-16	13D/A	Sindlev Rene	10.28	35.49

Top 13F Investors	Shares (1000)	Change (%)	Value ($1000)	Change (%)
(click for more detail)

Date	Insider Trades	Code	Shares	Value
(click for more detail)

File Date	Form	SEC Filings
2024-11-14	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-10-28	10-K/A	United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION report under sec
2024-10-10	10-K	United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION report under section 13 Or 15(d) o
2024-08-20	10-Q/A	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-05-15	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 1
2024-02-14	10-Q	U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTIO
(click for more detail)

Short Volume
Market Date	Short Volume	Total Volume	Short Volume Ratio
2024-11-29	211,076	867,208	24.34
2024-11-27	83,258	585,586	14.22
2024-11-26	168,381	425,982	39.53
2024-11-25	51,056	225,885	22.60
(click for more detail)

Similar Companies
PTPI – Petros Pharmaceuticals, Inc.	PULM – Pulmatrix, Inc.
QLGN – Qualigen Therapeutics, Inc.	REVB – Revelation Biosciences, Inc.
RGC – Regencell Bioscience Holdings Limited

Financial data and stock pages provided by
Fintel.io

Related